Biochemistry of Schizophrenia and Addiction

Section 1: Pathogenesis.- 1 The role of a prostaglandin E1 deficiency in schizophrenia: interactions with dopamine and opiates.- 2 The pathogenesis of schizophrenia.- 3 Opiates, opioid peptides and their possible relevance to schizophrenia.- 4 The possible actions of peptides with opioid activity derived from pepsin hydrolysates of wheat gluten and other constituents of gluten in the function of the central nervous system.- 5 Preliminary studies of the identification of brain peptides in relation to the genesis and expression of schizophrenia.- 6 The role of the dopamine system in schizophrenia.- Section 2: Immunology.- 7 The relevance of immunopathology to research into schizophrenia.- 8 Some connections between immunoglobulins and schizophrenia.- 9 Antibodies to wheat proteins in schizophrenia: relationship or coincidence?.- 10 The effects of hormones on immune responses.- 11 Binding of chlorpromazine and HLA-A1 antibodies to human lymphocyte membranes.- 12 The possible role of a prostaglandin Ea deficiency in the immunological abnormalities seen in schizophrenia.- 13 Immunological reaction of psychotic patients to fractions of gluten.- Section 3: Addiction.- 14 ß-endorphin and endoloxone: messengers of the autonomic nervous system for the conservation or expenditure of bodily resources and energy in anticipation of famine or feast.- 15 The pharmacology of tobacco smoking in relation to schizophrenia.- 16 Alcoholism and schizophrenia: a basic science approach.- 17 Opiate dependence and tolerance: a pharmacological analysis.- Section 4: Puerperal Psychoses.- 18 Puerperal schizophrenia?.- Section 5: Enzymology.- 19 The digestion and absorption of dietary protein.- Section 6: Physiology.- 20 Correlation between behavioural responses and cardiovascular changes and the central nervous mechanisms responsible for them.- Section 7: Morbidity and Mortality.- 21 Schizophrenia and physical disease: a preliminary analysis of data from the Oxford Record Linkage Study.- Section 8: Drug Treatments.- 22 Depot neuroleptics and tardive dyskinesia: prospective study.- 23 Recent developments in the drug treatment of schizophrenia.